The FDA has granted Priority Review to AstraZeneca’s Calquence (acalabrutinib) for the treatment of previously untreated mantle cell lymphoma (MCL). This decision follows promising results from the ECHO Phase III trial, which demonstrated that Calquence, in combination with bendamustine and rituximab, significantly reduced the risk of disease progression or death compared to standard-of-care chemotherapy.
The global breast cancer treatment landscape is evolving rapidly, with over 100 pharmaceutical companies actively developing new therapies to combat this prevalent disease. DelveInsight’s ‘Breast Cancer Pipeline Insight 2024’ report highlights the robust pipeline, featuring 120+ potential breast cancer drugs in various stages of clinical development. This report provides a comprehensive overview of the latest advancements, key players, and promising therapies on the horizon.
The renal cancer treatment landscape is evolving rapidly, with over 75 pipeline therapies in development by major pharmaceutical companies. This report analyzes the current state of the renal cancer pipeline, highlighting key companies, promising therapies, and recent advancements in clinical trials.
The FDA has approved Sanofi’s Sarclisa (siltuximab) in combination with VRd as a first-line treatment for adult patients with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. This approval makes Sarclisa the first anti-CD38 therapy in combination with VRd to significantly reduce disease progression or death in this patient population.
Achilles Therapeutics, a biotechnology company focusing on cancer treatment, announced a strategic shift away from its TIL-based cNeT program. This decision led to the discontinuation of ongoing Phase I/IIa clinical trials and a surge in the company’s share price. The company will now focus on collaborations with third parties developing alternative modalities for targeting clonal neoantigens in cancer treatment.
Galmed Pharmaceuticals’ shares are skyrocketing after the company announced ambitious plans to broaden its drug development activities, focusing on novel Aramchol-based drug combinations to combat resistant cancers and cardiac fibrosis. This expansion, coupled with Galmed’s low float and micro-cap status, has fueled significant volatility in the stock.
The FDA has approved Merck’s Keytruda in combination with chemotherapy for the first-line treatment of malignant pleural mesothelioma (MPM). This approval marks the first indication for Keytruda in MPM in the U.S. and is based on clinical trial data showing significant improvements in overall survival and progression-free survival compared to chemotherapy alone.
Influencer Fabiana Justus, diagnosed with Acute Myeloid Leukemia earlier this year, continues to share her journey through treatment following a bone marrow transplant. In recent videos, she updates her followers on her progress, including a new round of tests at the hospital and the challenges she faces with ongoing medication.
NuCana plc presented promising data from its Phase 2 NuTide:701 study, showcasing the potential of NUC-7738 in combination with Merck’s Keytruda for treating metastatic melanoma. The combination showed encouraging efficacy signals and a favorable safety profile in patients who had previously failed PD-1 inhibitor therapies.
Johnson & Johnson’s Rybrevant, a lung cancer treatment, continues to demonstrate positive results. A new study shows that a prophylactic strategy significantly reduces infusion-related reactions, while long-term data from the MARIPOSA study reinforces Rybrevant’s effectiveness in combination with Lazcluze, improving survival and disease control compared to standard treatment.
